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Abstract
Background: Chemotherapy combined concurrently with TKIs produced a negative interaction and failed to
improve survival when compared with chemotherapy or TKIs alone in the treatment of non-small cell lung cancer
(NSCLC). The present study investigated the sequence-dependent interaction between paclitaxel and gefitinib and
clarified the underlying mechanism.
Methods: The effects on cell proliferation, EGFR signaling pathway, and TGFa expression were evaluated in a panel
of human NSCLC cell lines harboring EGFR mutations with three different combination sequences: sequential
treatment with paclitaxel followed by gefitinib (T®G), sequential treatment with gefitinib followed by paclitaxel
(G®T), or concomitant treatment (T + G).
Results: The sequence-dependent anti-proliferative effects differed between EGFR-TKI-sensitive and -resistant cell
lines carrying EGFR mutations. A synergistic anti-proliferative activity was obtained with paclitaxel treatment
followed by gefitinib in all cell lines, with mean CI values of 0.63 in Hcc827, 0.54 in PC-9, 0.81 in PC-9/GR, and 0.77
in H1650 cells for the T®G sequence. The mean CI values for the G®T sequence were 1.29 in Hcc827, 1.16 in PC-
9, 1.52 in PC-9/GR, and 1.5 in H1650 cells. The mean CI values for T+G concomitant treatment were 0.88 in Hcc827,
0.91 in PC-9, 1.05 in PC-9/GR, and 1.18 in H1650 cells. Paclitaxel produced a dose-dependent increase in EGFR
phosphorylation. Paclitaxel significantly increased EGFR phosphorylation compared with that in untreated controls
(mean differences: +50% in Hcc827, + 56% in PC-9, + 39% in PC-9/GR, and + 69% in H1650 cells; p < 0.05). The
T®G sequence produced significantly greater inhibition of EGFR phosphorylation compared with the opposite
sequence (mean differences: -58% in Hcc827, -38% in PC-9, -35% in PC-9/GR, and -30% in H1650 cells; p < 0.05).
Addition of a neutralizing anti-TGFa antibody abolished paclitaxel-induced activation of the EGFR pathway in PC-9
and H1650 cells. Sequence-dependent TGFa expression and release are responsible for the sequence-dependent
EGFR pathway modulation.
Conclusion: The data suggest that the sequence of paclitaxel followed by gefitinib is an appropriate treatment
combination for NSCLC cell lines harboring EGFR mutations. Our results provide molecular evidence to support
clinical treatment strategies for patients with lung cancer.
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Despite recent advances in early diagnosis and treat-
ment, non-small cell lung cancer (NSCLC) is still a dis-
ease with a poor prognosis. Platinum-based doublet
chemotherapy is the mainstay of treatment for advanced
NSCLC with good performance status [1,2]. Current
data suggest that NSCLC chemotherapy has reached a
therapeutic plateau [3,4].
Gefitinib and erlotinib are orally active, reversible
Her-1/epidermal growth factor receptor tyrosine
kinase inhibitors (EGFR-TKIs). In 2004, researchers
found that EGFR-activating mutations correlated with
clinical responses [5-7]. The Iressa Pan-Asia Study
(IPASS) trial indicated that gefitinib was superior to
carboplatin plus paclitaxel as an initial treatment for
patients with advanced NSCLC harboring an EGFR
mutation [8]. The finding was further supported by
two randomized studies (the WJTOG3405 and NEJ
002 trials) that consistently reported a high tumor
response rate and progression-free survival (PFS) in
patients with an EGFR mutation [9,10]. The EGFR
mutation rate was higher in Asian than in western
patients, explaining the higher response rate in East
Asian patients [11]. Based on these studies, an EGFR
mutation is currently the only established predictive
factor for EGFR-TKIs.
An increasingly interesting area of clinical research is
the development of rationale combinations of cytotoxic
drugs with molecularly targeted therapies to increase
the therapeutic potential by blocking cancer cell survi-
val mechanisms. Recently, we have shown that the
sequence of paclitaxel followed by gefitinib improves
the antiproliferative effect compared with other
sequences and produced a synergistic effect. We also
found the sequence-dependent modulation of EGFR
phosphorylation plays a role in this sequence-dependent
antiproliferative effect [12]. However, we did not focus
on cell lines with mutant EGFR and the exact mechan-
ism underlying the modulation of EGFR phosphoryla-
tion remains to be determined. While other studies
indicated that TGFa release is responsible for EGFR
activation induced by radiotherapy [13,14], we hypothe-
sized that TGFa might play a role in the sequence-
dependent antiproliferative effect.
Thus, the present study was performed in NSCLC cell
lines harboring EGFR-activating mutations to investigate
the synergistic interaction between paclitaxel and gefiti-
nib, and to determine the underlying mechanism(s). We
found that sequence-dependent TGFa expression and
release were responsible for the sequence-dependent
EGFR pathway modulation and sequence-dependent
antiproliferative effect.
Materials and methods
Drugs and chemicals
Pure gefitinib, kindly provided by AstraZeneca (London,
UK), was dissolved in dimethyl sulfoxide (DMSO) as a
20 mM stock solution. Paclitaxel was purchased from
S i g m a( S t .L o u i s ,M O ,U S A )a n dw a sd i s s o l v e di n
DMSO as a 1 mM stock solution. Both drugs were
diluted with culture medium before use.
Primary antibodies: anti-pY1068 EGFR (phosphotyro-
sine-specific EGFR antibody) and anti-b-actin were
purchased from Cell Signaling Technology (Danvers,
MA, USA), anti-EGFR was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA), and anti-TGFa
antibody[189-2130.1] was purchased from Abcam (Cam-
bridge, MA, USA).
Cell lines
The human lung adenocarcinoma cell lines PC-9,
Hcc827, and H1650 were kindly provided by Dr. Tony
Mok (Chinese University of Hong Kong). These cell
lines have been extensively characterized. PC-9 is
derived from a patient with adenocarcinoma, harboring
an EGFR exon 19 in-frame deletion[E746-A750] that is
highly sensitive to EGFR-TKIs [15], Hcc827 is derived
from lung adenocarcinomas harboring an EGFR exon 19
in-frame deletion that is highly sensitive to EGFR-TKIs
[16]. H1650 carries an EGFR exon 19 in-frame deletion
mutation and is resistant to EGFR-TKIs. Martin et al.
reported the homozygous de l e t i o no fP T E Ni nH 1 6 5 0
cells, which activated EGFR and contributed to erlotinib
resistance [17]. PC-9/GR is a gefitinib-acquired resistant
cell line that was established by chronic exposure of PC-
9 cells to medium with increasing concentrations of
gefitinib. Briefly, PC-9 cells were exposed to 10 nmol/L
of gefitinib in medium containing 10% fetal bovine
serum, and the concentration was increased in a step-
wised manner. Cells that were able to grow in 1 μmol/L
gefitinib were obtained 6 month after initial expose. The
decreased sensitivity did not recover even the cells were
kept in culture for > 4 month without gefitinib. These
cells were grown in RPMI 1640 medium supplemented
with 10% fetal bovine serum (FBS), penicillin (100 UI/ml),
and streptomycin (100 μg/ml) at 37°C in a humidified
atmosphere with 5% CO2 and harvested with trypsin-
EDTA when the cells were in exponential growth.
Sequencing of EGFR gene
The exons encoding the intracellular domain of EGFR
were amplified from genomic DNA and directly
sequenced. To further characterize additional mutation,
we amplified the EGFR exon 19 to 20 from PC-9 or PC-
9/GR cDNA, and the PCR products were subcloned
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sequenced.
Treatment regimens
Cell viability was determined using the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide)
assay, according to the method of Mosmann and Carmi-
chael [18,19]. To evaluate the antiproliferative effects of
combined treatment, cells were treated with three differ-
ent sequences: I, pretreated with paclitaxel for 24 h,
aspirated and washed once with phosphate-buffered sal-
ine (PBS), followed by gefitinib for 48 h; II, pretreated
with gefitinib for 48 h, aspirated and washed once with
PBS, followed by paclitaxel for 24 h; III, treated conco-
mitantly with paclitaxel plus gefitinib for 48 h, and then
incubated in drug-free medium for 24 h. The different
drug doses were combined using constant ratios of the
IC50 values, calculated from previous cytotoxicity tests.
T h u s ,w eu s e d0 . 1 2 5 ,0 . 2 5 ,0 . 5 ,1 ,2 ,a n d4t i m e st h e
IC50 dose in paclitaxel and gefitinib combination doses
to calculate the CI value. The results of sequential treat-
ment with paclitaxel and gefitinib were analyzed accord-
ing to the method of Chou and Talaly [20]. The
resulting combination index (CI) represented a quantita-
tive measure of the degree of interaction between differ-
ent drugs, with CI > 1.1, CI = 0.9-1.1, and CI < 0.9
indicating antagonistic, additive, and synergistic effects,
respectively. The CI value was calculated using the
CompuSyn software (ComboSyn, Inc., Paramus, NJ,
USA).
Western blot analysis
Cells were seeded at 1 × 10
5 per plate on 10-cm plates
and left to settle overnight. Cells were then treated by
adding fresh medium containing drugs for the desired
times. Soluble protein was extracted with the addition of
RIPA lysis solution. Lysates were cleared by centrifuga-
tion (12000 rpm, 4°C, 15 min), and soluble protein
extracts were stored frozen at -80°C. Protein concentra-
tions were quantitated using the bicinchoninic acid
assay [21]. Total cell extracts (30 μg of protein/well)
were resolved on 8-10% acrylamide Tris-acetate gels,
and then proteins were transferred to a polyvinylidene
fluoride (PVDF) membrane, blocked for 1 h at room
temperature in 5% w/v non-fat milk diluted in Tris-
buffered saline Tween 20 (TBST), and finally incubated
with appropriate primary antibodies under the condi-
tions recommended by the manufacturers. The blots
were then washed with TBST for 30 min and incubated
with horseradish peroxidase-conjugated secondary anti-
body at room temperature for 1 h. Antibody binding
was detected using an enhanced chemiluminescence
system(Santa Cruz, CA, USA).
To quantify protein levels, films were scanned and
analyzed with the Labworks software(World BioHazTec
C o r p ,N M ,U S A ) .T h er e l a t i ve protein levels were
counted using a comparison with the untreated control.
Real-time polymerase chain reaction (PCR)
To compare the possible influence of TGFa gene
expression on the sequence-dependent synergistic
effect between paclitaxel and gefitinib, we used PC-9
cells to analyze the sequential modulation of TGFa
expression. The primer and probe design, total RNA
isolation, cDNA synthesis, and quantification standards
for real-time PCR were performed as described
previously [22,23]. Total RNA was isolated using the
Trizol reagent (Invitrogen) according to the manufac-
turer’s protocol. The integrity of the total RNA was
examined by 1% agarose gel electrophoresis, the quan-
tity was determined based on the absorbance at 260
nm (A260), and the purity was analyzed based on the
absorbance ratio at 260 and 280 nm. For pure RNA
the ratio of A260/280 is ~2.0(A260/280;A m e r s h a mB i o s -
ciences GeneQuant, Pittsburgh, PA, USA). cDNA was
synthesized from total RNA (1 μg) using AMV reverse
transcriptase XL (Takara Bio, Inc., Shiga, Japan). b-
actin served as an internal control. To create real-time
PCR standards, TGFa and b-actin were amplified
using reverse transcriptase-PCR and specific primers.
The amplicons were cloned into the pMD18-T vector
(Takara) and the sequence was confirmed by sequen-
cing. The purified recombinant DNA was quantified
and then serially diluted in ultra-pure water to a final
concentration ranging from 10
7 to 10
1 copies/μL. For
quantification standards, we used 1-μL aliquots of
10-fold serial dilutions of plasmid DNA. A new stan-
dard curve was run for each real-time PCR, and each
test run included a control containing non-target
DNA. The amount of TGFa mRNA was normalized
to the expression values of the housekeeping gene
b-actin.
TGFa enzyme-linked immunosorbent assay (ELISA)
Medium was harvested from cells grown on 6-well
dishes. Samples were processed using the human TGFa
quantikine ELISA kit (R&D systems, Inc., Minneapolis,
MN, USA) according to the manufacturer’s instructions.
Statistics
Results are presented as the mean ± standard error (SE)
of at least three experiments. Statistical comparisons of
sequence-dependent effects were conducted by student’s
t tests. Statistics and graphs were generated using the
GraphPad Prism software (ver. 5.00 for windows, Graph-
Pad Software Inc, CA, USA).
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The potential mechanisms for gefitinib resistance in PC-9/
GR cells
The gefitinib-acquired resistant PC-9/GR cells were
obtained 6 months after initial exposure. These cells
were 100-fold more resistant than parental cells(Table-1).
Additional mutations were not detected by direct
sequencing. The PCR product of PC-9 and PC-9/GR
were subcloned into a plasmid vector, then the inserts
were randomly selected and sequenced. Among the 20
sequences from PC-9/GR, we found 6 sequences were
wild-type, 11 had only the 15-bp deletion, and 3 had both
the 15-bp deletion and T790M mutation. These T790M
mutation seemed to be the cause of gefitinib resistance.
Of 10 colones isolated from PC-9, 4 had no mutation,
and the others had the 15-bp deletion (Figure 1).
Sequence-dependent antiproliferative effects differed
between EGFR-TKI-sensitive and EGFR-TKI-resistant NSCLC
cell lines
To evaluate the antiproliferative effects of paclitaxel and
gefitinib treatment, we performed a series of MTT cell
growth assays. Treatment with gefitinib alone for 72 h
resulted in a dose-dependent inhibition of cancer cell
growth. Table 1 summarizes the IC50 of these two
drugs. PC-9 and Hcc827 were highly sensitive to gefiti-
nib, while H1650 exhibited primary resistance and PC-
9/GR showed acquired resistance to gefitinib. All of
these cell lines demonstrated similar sensitivities to
paclitaxel. We evaluated the growth inhibition effect on
Hcc827, PC-9, PC-9/GR, and H1650 of three different
sequences of combined paclitaxel and gefitinib treat-
ments. Figure 2a shows the schema for in vitro sequen-
tial treatment between paclitaxel and gefitinib. As
shown in Figure 2b and 2c, the antiproliferative effects
between paclitaxel and gefitinib were sequence-depen-
dent. Although the differences were not marked, the
sequence of paclitaxel followed by gefitinib was most
efficacious against EGFR-mutant NSCLC cells.
The calculation of CI values revealed that the
sequence of paclitaxel followed by gefitinib produced
synergistic effects. In Hcc827 and PC-9 cell lines,
which were highly sensitive to EGFR-TKIs, the
sequence of paclitaxel followed by gefitinib resulted in
synergistic effects, with mean CI values of 0.63 in
Hcc827, 0.54 in PC-9. Concomitant administration of
the drugs resulted in both synergistic and additive
effects, with mean CI values of 0.88 in Hcc827, 0.91 in
PC-9. The gefitinib followed by paclitaxel sequence
resulted in an additive and antagonistic interaction
with mean CI values of 1.29 in Hcc827, 1.16 in PC-9
(Figure 3a,b). In the PC-9/GR cell line, which exhibited
acquired resistance to EGFR-TKIs, the sequence of
paclitaxel followed by gefitinib resulted in a synergistic
and additive interaction with increasing drug concen-
trations (mean CI, 0.81). In contrast, the sequence of
gefitinib followed by paclitaxel resulted in an antago-
nistic effect (mean CI, 1.52). Concomitant treatment
with the two drugs resulted in additive and antagonis-
tic effects (mean CI, 1.05)(Figure 3c). In the H1650
cell line, a synergistic and additive growth inhibition
effect was found with the sequence of paclitaxel fol-
lowed by gefitinib (mean CI, 0.77). In contrast, the
sequence of gefitinib followed by paclitaxel resulted in
an antagonistic interaction (mean CI, 1.5). Simulta-
neous administration of the two drugs resulted in an
additive and antagonistic interaction (mean CI, 1.18)
(Figure 3d). Each experiment was repeated in triplicate.
Sequence-dependent modulation of the EGFR signaling
pathway
To gain insight into the mechanisms involved regulating
the interaction between paclitaxel and gefitinib, we
examed the effect of paclitaxel on EGFR phosphoryla-
tion. In cell lines of PC-9 and H1650, a dose-dependent
increase in pEGFR levels were observed 24 hous after 1,
2a n d3f o l dI C 5 0d o s eo fp a c l i t a x e le x p o s u r e ( F i g u r e4 ) .
Because EGFR-TKIs specifically target the tyrosine
kinase activity of EGFR, we analyzed the sequence-
dependent modulation of the EGFR signaling pathway
using an IC50 dose of paclitaxel plus gefitinib combina-
tion. As shown in Figure 5, gefitinib significantly inhib-
ited EGFR phosphorylation (p < 0.01). When Hcc827,
PC-9, PC-9/GR and H1650 cell lines were exposed to
paclitaxel alone, phosphorylated EGFR (pEGFR) levels
increased significantly after paclitaxel exposure for 24 h
than that in untreated control (mean difference, +50%
in Hcc827, +56% in PC-9, +39% in PC-9/GR and +69%
in H1650 cells respectively, p < 0.05). The increase in
pEGFR induced by paclitaxel was blocked by adding
gefitinib. In the reverse sequence, gefitinib treatment for
48 h significantly inhibited pEGFR levels, compared with
the untreated control level of pEGFR, and subsequent
paclitaxel exposure for 24 h enhanced pEGFR levels.
The paclitaxel followed by gefitinib sequence produced
significantly greater pEGFR inhibition than did the
reverse sequence (mean difference, -58% in Hcc827,
-38% in PC-9, -35% in PC-9/GR and -30% in H1650
respectively, p < 0.05).
These data suggest that paclitaxel may also have a
self-limiting effect on its toxicity, via activation of the
EGFR tyrosine kinase phosphorylation, leading to
increased proliferation and survival of paclitaxel-
mediated cytotoxicity. The increase in pEGFR can be
blocked by adding gefitinib, which produces a synergis-
tic effect. In the reverse sequence, however, the
sequence of gefitinib followed by paclitaxel interferes
with the inhibition of pEGFR by gefitinib.
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by a neutralizing antibody to TGFa
Several studies have demonstrated that chemotherapy
activates EGFR phosphorylation [24]. Multiple mechan-
isms allow for EGFR activation and persistent tumor
cell proliferation, including activating mutations, recep-
tor amplification, and ligand up-regulation [25,26].
Other studies have found that radiation causes release
of TGFa, which is responsible for activation of the
EGFR signaling pathway [13]. We next examined
whether activation of the EGFR signaling pathway
induced by paclitaxel is dependent on TGFa.P a c l i t a x e l
caused EGFR activation in PC-9 and H1650 cells after a
12-h exposure and lasted for 48 h. Addition of a neutra-
lizing antibody to TGFa reduced the activation of EGFR
(Figure 6). These data demonstrated that paclitaxel-
induced EGFR activation was dependent on the function
of TGFa.
Figure 1 P C - 9 / G Re x o n2 0s e q u e n c e .A .W i l dt y p eb yd i r e c ts e q u e n c i n g .B .3o f2 0c l o n e sh a dA C G>A T GT 7 9 0 Mm u t a t i o nb yc l o n e
sequencing. C. 17 of 20 clones were wild type.
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phosphorylation of the receptor. We then determine the
growth inhibition effect of an anti-TGFa antibody. PC-9
and H1650 cells were grow into the medium containing
increasing concentration of anti-TGFa antibody for 72
hours. The antibody show a modest growth inhibition
effect, inhibited the growth of PC-9 and H1650 by
about 30% at 500 ng/ml (Figure 7).
Sequence-dependent TGFa expression and release are
responsible for the sequence-dependent EGFR pathway
modulation
To further evaluate whether sequential modulation of
the EGFR pathway is due to the release of TGFa,P C - 9 ,
Hcc827 and H1650 cells were treated with sequential
paclitaxel and gefitinib as indicated in the treatment
schema of Figure 2a. Medium was subjected to ELISA
to verify soluble TGFa levels and was normalized to cell
numbers. As shown in Figure 8a, paclitaxel exposure for
24 h significantly stimulated TGFa release. Gefitinib sig-
nificantly inhibited the release of TGFa (p < 0.05). The
paclitaxel-followed-by-gefitinib sequence resulted in a
significant reduction of TGFa levels, compared with the
reverse sequence (p < 0.05).
To gain further insight into the mechanisms involved
in regulating the interaction between paclitaxel and gefi-
tinib, we examined changes in TGFa mRNA expression
in treated PC-9, Hcc827 and H1650 cells. Quantitative
PCR analysis of TGFa mRNA expression levels showed
that in comparison with the respective control, pacli-
taxel significantly increased (p <0 . 0 1 ) ,w h i l eg e f i t i n i b
significantly decreased TGFa mRNA expression (p <
0.05). The paclitaxel-followed-by-gefitinib sequence sig-
nificantly decreased TGFa mRNA expression, compared
with the reverse sequence (Figure 8b; p < 0.05).
Discussion
The present study demonstrated that the antiprolifera-
tive effect with paclitaxel and gefitinib is sequence-
dependent in EGFR-mutant NSCLC cells. We found
that the sequence of paclitaxel followed by gefitinib
Table 1 IC50 values for each drug were calculated by
performing dose response experiments with gefitinib
and paclitaxel
IC50 Hcc827 PC-9 PC-9/GR H1650
Paclitaxel 2.27 ±
0.15nM
2.33 ±
0.47nM
2.59 ±
0.62nM
3.29 ±
0.35nM
Gefitinib 16 ± 1.12nM 19 ± 2nM 2.1 ± 0.39 μM 9.37 ±
0.52μM
Figure 2 The antiproliferative effect with paclitaxel and gefitinib is sequence-dependent. A. Schema of sequential treatment. B and C. The
sequence of paclitaxel followed by gefitinib produced the most potent antiproliferative effect in PC-9 and Hcc827 cells. T ® G, paclitaxel
followed by gefitinib. G ® T, gefitinib followed by paclitaxel. T + G, concomitant paclitaxel and gefitinib. T, paclitaxel alone for 72 h. G, gefitinib
alone for 72 h.
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Other studies have demonstrated sequence-dependent
interaction between EGFR-TKIs and chemotherapy in
human cancer cell lines [27]. These studies also revealed
that pretreatment with erlotinib caused G1 arrest and
effectively abrogated the activity of chemotherapy,
resulting in decreased cytotoxicity and decreased apop-
tosis [28-30]. Solit et al. reported schedule-dependent
efficacy in an NSCLC xenograft model with paclitaxel
and gefitinib [31]. Our study was novel because we
found that sequence-dependent modulation of the
EGFR signaling pathway might play a role in the
sequence-dependent interaction in NSCLC cells harbor-
ing an EGFR mutation. We found that paclitaxel-
induced activation of EGFR was dependent on the func-
tion of TGFa. Additionally, TGFa expression and
release were sequence-dependent, which may responsi-
ble for the sequence-dependent interaction between
paclitaxel and gefitinib.
As EGFR-TKIs gefitinib and erlotinib are active in
patients with NSCLC harboring EGFR mutations, com-
bining them in treatment with chemotherapy was
deemed promising [8,9]. However, in the INTACT-1,
INTACT-2, TALENT, and TRIBUTE clinical trials, the
addition of gefitinib or erlotinib to first-line chemother-
apy failed to improve survival [32-35]. In a phase II trial
of CALGB 30406, the concurrent combination of pacli-
taxel plus carboplatin with erlotinib showed a similar
efficacy compared with erlotinib alone in patients with
advanced lung adenocarcinoma [36]. Gandara et al.
[37,38] proposed two hypotheses that seem reasonable to
explain the negative results. First, patients were not
selected based on a predictive response marker, although
other studies have reported that activating mutations in
the EGFR tyrosine kinase domain were associated with a
dramatic response to gefitinib and erlotinib. Second,
potentiation of the antagonistic interaction between con-
current EGFR-TKI and chemotherapy may have played a
role, because in vitro and in vivo studies of administration
of concurrent EGFR-TKI and chemotherapy have sug-
gested antagonism. Davies et al. [39] have proposed the
pharmacodynamic separation model: EGFR-TKIs primar-
ily cause cell cycle arrest and accumulation of cells in G1;
and thus, when administered concurrently with che-
motherapy, can interfere with cell cycle-specific cytotoxi-
city. Our previous study [12] and other study [30] found
that EGFR-TKI induces G1 arrest, which produced a
negative interaction when combined concurrently with
chemotherapy or followed by chemotherapy.
Chemotherapy has been shown to activate multiple
signaling pathways [40] and, recently, to activate the
EGFR pathway as well as to enhance ubiquitination and
degradation [41,42]. The intracellular TK activity of
EGFR is increased as a consequence of binding of var-
ious cognate ligands, including EGF, TGFa, and amphir-
egulin, leading to homodimerization of two EGFRs or
Figure 3 Synergism of sequence-dependent cytotoxicity between paclitaxel and gefitinib. Points, mean values of three different
experiments. ○ T ® G, paclitaxel followed by gefitinib. □ G ® T, gefitinib followed by paclitaxel. △ T + G, concomitant paclitaxel and gefitinib.
The sequence T ® G produced the most potent cytotoxic growth inhibition. The T ® G sequence resulted in a synergistic effect.
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dose-dependent increase in EGFR phosphorylation levels were observed.
Figure 5 Sequential modulation of EGFR phosphorylation. Cells were exposed to the IC50 dose of gefitinib and paclitaxel using different
sequences. *Paclitaxel significantly activated the EGFR pathway compared with control after paclitaxel exposure for 24 h (p < 0.05). # p < 0.05.
The phosphorylated EGFR (p-EGFR) level after treatment with paclitaxel followed by gefitinib was lower than that for gefitinib followed by
paclitaxel.
Cheng et al. Journal of Hematology & Oncology 2011, 4:5
http://www.jhoonline.org/content/4/1/5
Page 8 of 13heterodimerization of EGFR with other family members
[43]. Improper activation of EGFR TK results in
increased malignant cell survival, proliferation, invasion,
and metastasis [44,45]. Several chemotherapy drugs
were found to activate the EGFR signaling pathway [41].
Radiation has also been demonstrated to activate the
EGFR signaling pathway by causing the release of
TGFa, which is responsible for secondary activation of
EGFR, mitogen-activated protein kinase (MAPK), and
Janus kinase (JNK) pathways [13]. In the present study,
neutralizing TGFa abolished the paclitaxel induced-
activation of EGFR, and paclitaxel may stimulate release
of TGFa to activate the EGFR pathway.
Autocrine loops are established when soluble factors
secreted by cells bind to and stimulate receptors on
their own surfaces [46]. TGFa is a cognate ligand for
EGFR and can establish an autocrine loop that leads to
receptor hyperactivity [47]. Ciardiello, et al. found that a
TGFa-EGFR autocrine growth pathway is active in can-
cer cell lines, and gefitinib produced a dose-dependent
inhibition of the secretion of TGFa [48]. Our data sug-
gest that paclitaxel may exert a self-limiting effect on its
Figure 6 Paclitaxel-induced activation of EGFR is blocked by adding neutralizing TGFa antibody. The dose of paclitaxel is 2-fold IC50. The
dose of TGFa antibody is 0.15 μg/mL A.PC-9 B. H1650.
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Page 9 of 13Figure 7 Growth inhibition of PC-9 and H1650 by an anti-TGFa.antibody. PC-9 and H1650 cells were grow into a 96 well plate. The
following day, the cells were incubated with indicated concentration of anti-TGFa antibody for 72 h. The inhibition ratio were determined by
MTT assay.
Figure 8 Sequential modulation of TGFa release and expression. Cells were exposed to IC50 dose of paclitaxel and gefitinib with different
sequence. A, standard enzyme-linked immunosorbent assay analysis of soluble TGFa levels in PC-9, Hcc827 and H1650 cells. *p < 0.05,
significantly different from control. #P < 0.05, T®GV SG ®T. B, reverse transcription-polymerase chain reaction analysis of TGFa expression. *p <
0.05, significantly different from control. #P < 0.05, T®G vs. G®T.
Cheng et al. Journal of Hematology & Oncology 2011, 4:5
http://www.jhoonline.org/content/4/1/5
Page 10 of 13ability to kill and reduce the proliferation of autocrine-
regulated tumor cells, potentially by increasing both the
rates of transcription and activation of TGFa.I n c r e a s e d
expression and release of TGFa leads to both increased
EGFR and activation of the downstream signaling path-
way, which, in turn, leads to both increased proliferation
of tumor cells as well as other enhanced cytoprotective
responses. Increased TGFa expression and release can
be blocked by subsequent administration of gefitinib,
which can block TGFa-triggered EGFR signaling path-
way activation and produce a synergistic effect. In con-
trast, initial exposure to gefitinib decreases TGFa
expression and release, and subsequent paclitaxel treat-
ment enhances TGFa expression and release, producing
an antagonistic effect.
Cytotoxic chemotherapy treatment for patients with
advanced NSCLC has reached a plateau, but further
improvements are expected with the integration of tar-
geted therapies [49,50]. EGFR-TKIs treatment concur-
rent with chemotherapy failed to improve survival.
Alternative schedules of TKI administration in combina-
tion with chemotherapy, such as sequential and pulse
administration, are under investigation. In the Fast-Act
trial, a randomized phase II trial of sequential erlotinib
and chemotherapy as first-line treatment of patients
with advanced NSCLC, gemcitabine plus cisplatin or
carboplatin (GC) were sequentially followed by erlotinib
(GC-E) versus GC followed by a placebo (GC-P). The
results revealed that GC-E significantly improved PFS
compared with GC-P [51]. Based on these results, Fast-
Act II, a randomized phase III trial of sequential erloti-
nib and chemotherapy, is underway [52].
In the final analysis of the pivotal IPASS trial,
although there is significant improvement in PFS and
RR for patients receiving gefitinib, overall survival was
similar for gefitinib and carboplatin/paclitaxel, reported
Chin-Hsin Yang [53]. The effect of the initial rando-
mized treatment therapy on overall survival is likely to
have been confounded by subsequent study, particulary,
the switching of patients to the alternative study treat-
ment. This suggests the sequence of therapy may not
make a significant impact in patients with mutant
EGFR, as long as such patients are exposed to an EGFR
TKI in general, and whether it is given first-line or later
translates into the same overall survival benefit.
The limitation of this study is that because the short
exposure time, the interaction of sequential treatment in
vitro may not correlate the interaction between first-line
and second-line treatment in clinic. The drug interac-
tion patterns observed in vitro may not be similar to
those observed clinically. Because the culture condition
can perturb cell function and potentiate drug sensitivity,
obtaining good correlations can be problematic. Phar-
macokinetics, pharmacodynamics, rescue effects and
toxicity to normal cells/tissues that affect drug action in
clinical setting are not considered by in vitro assays.
Because each patient has a unique pharmacogenetic
makeup, correlating in vitro and clinical results is often
not a straightforward process. However, our study pro-
vided a rational for the ongoing clinical investigation of
sequential treatment of NSCLC.
Conclusions
In summary, our studies have demonstrated that
sequential administrations of paclitaxel followed by gefi-
tinib result in the most effective cytotoxic effects in
NSCLC cell lines harboring EGFR mutations. The
sequence-dependent modulation of TGFa expression
and release might be responsible for the synergistic
interaction between paclitaxel and gefitinib. Although
the extrapolation of in vitro data to the clinical setting
should be considered with caution, these results may
have implications for the rational development of che-
motherapeutic regimens for the treatment of NSCLC.
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